What is the current Price Target for the Zentalis Pharmaceuticals Inc stock?

The average Zentalis Pharmaceuticals Inc target price is $6.27. This is 387.94% higher than the current stock price. The highest price target is 678.21%, the lowest is 71.21%. 10 Analysts have issued a price target Zentalis Pharmaceuticals Inc 2026 .

How high will the Zentalis Pharmaceuticals Inc stock rise?

No reliable answer can be given as to how high the Zentalis Pharmaceuticals Inc stock will rise. The performance of stocks, including the Zentalis Pharmaceuticals Inc stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Zentalis Pharmaceuticals Inc stock today?

The performance of Zentalis Pharmaceuticals Inc stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Zentalis Pharmaceuticals Inc stock fall?

The decline in Zentalis Pharmaceuticals Inc stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Zentalis Pharmaceuticals Inc Forecast, price target & analysts

$1.16

9.73% today

Nasdaq, Apr 04, 09:18 pm CET

ISIN

US98943L1070

Symbol

ZNTL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Zentalis Pharmaceuticals Inc Target price 2025 - Analyst rating & recommendation

Zentalis Pharmaceuticals Inc Classifications & Recommendation:

Buy

45%

Hold

55%

Zentalis Pharmaceuticals Inc Price Target

Target Price	$6.27
Price	$1.29
Potential	387.94% register free of charge
Number of Estimates	10

	10 Analysts have issued a price target Zentalis Pharmaceuticals Inc 2026 . The average Zentalis Pharmaceuticals Inc target price is $6.27. This is 387.94% register free of charge higher than the current stock price. The highest price target is $10.00 678.21% register free of charge , the lowest is $2.20 71.21% register free of charge .
	A rating was issued by 11 analysts: 5 Analysts recommend Zentalis Pharmaceuticals Inc to buy, 6 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Zentalis Pharmaceuticals Inc stock has an average upside potential 2026 of 387.94% register free of charge . Most analysts recommend the Zentalis Pharmaceuticals Inc stock at Hold.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-2.33	-2.50
	47.87%	7.30%
P/E		negative

11 Analysts have issued a Zentalis Pharmaceuticals Inc forecast for earnings per share. The average Zentalis Pharmaceuticals Inc EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-2.33	47.87%
2025	$-2.50 7.30% Unlock
2026	$-2.37 5.20% Unlock
2027	$-1.93 18.57% Unlock
2028	$-1.68 12.95% Unlock
2029	$-0.83 50.60% Unlock

Current	-0.55	84.06%
2025	-0.51 7.27% Unlock
2026	-0.54 5.88% Unlock
2027	-0.67 24.07% Unlock
2028	-0.77 14.93% Unlock
2029	-1.55 101.30% Unlock

Zentalis Pharmaceuticals Inc...

Current Zentalis Pharmaceuticals Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Wedbush	Locked ➜ Locked	Locked	Mar 28 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Mar 27 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Mar 17 2025
Wells Fargo	Locked ➜ Locked	Locked	Jan 30 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Jan 29 2025
UBS	Locked ➜ Locked	Locked	Jan 28 2025
Guggenheim	Locked ➜ Locked	Locked	Nov 15 2024

Analyst Rating	Date
Locked Wedbush: Locked ➜ Locked	Mar 28 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Mar 27 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Mar 17 2025
Locked Wells Fargo: Locked ➜ Locked	Jan 30 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Jan 29 2025
Locked UBS: Locked ➜ Locked	Jan 28 2025
Locked Guggenheim: Locked ➜ Locked	Nov 15 2024

Discover more stocks with a high price target

Novo Nordisk 83.92%

Coinbase Global, Inc. 83.53%

BioNTech SE - ADR 50.09%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now